(Cell Reports) Topline results from a HEALEY platform trial showed that fosigotifator, an investigational eIF2B activator developed by the longevity company Calico Life Sciences in collaboration ...

The HEALEY platform trial is evaluating eIF2B agonist DNL343 in the treatment of amyotrophic lateral sclerosis (ALS). DNL343 is a novel small molecule ALS therapeutic candidate that targets eIF2B ...

2012;7(1):81-92. These recent findings have two important implications. First, simple measurements of eIF2B GEF activity in samples from patient-derived cells do not appear to be a suitable ...